IBDEI0XI ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16626,0)
 ;;=618.01^^108^1046^29
 ;;^UTILITY(U,$J,358.3,16626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16626,1,3,0)
 ;;=3^618.01
 ;;^UTILITY(U,$J,358.3,16626,1,4,0)
 ;;=4^Cystocele, Midline
 ;;^UTILITY(U,$J,358.3,16626,2)
 ;;=^331534
 ;;^UTILITY(U,$J,358.3,16627,0)
 ;;=621.30^^108^1046^38
 ;;^UTILITY(U,$J,358.3,16627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16627,1,3,0)
 ;;=3^621.30
 ;;^UTILITY(U,$J,358.3,16627,1,4,0)
 ;;=4^Endometrial Hyperplas NOS
 ;;^UTILITY(U,$J,358.3,16627,2)
 ;;=^331542
 ;;^UTILITY(U,$J,358.3,16628,0)
 ;;=626.2^^108^1046^41
 ;;^UTILITY(U,$J,358.3,16628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16628,1,3,0)
 ;;=3^626.2
 ;;^UTILITY(U,$J,358.3,16628,1,4,0)
 ;;=4^Excessive Menstrauation
 ;;^UTILITY(U,$J,358.3,16628,2)
 ;;=^75895
 ;;^UTILITY(U,$J,358.3,16629,0)
 ;;=V16.41^^108^1046^42
 ;;^UTILITY(U,$J,358.3,16629,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16629,1,3,0)
 ;;=3^V16.41
 ;;^UTILITY(U,$J,358.3,16629,1,4,0)
 ;;=4^Fam HX, Malig Neopl of Ovary
 ;;^UTILITY(U,$J,358.3,16629,2)
 ;;=^317951
 ;;^UTILITY(U,$J,358.3,16630,0)
 ;;=625.6^^108^1046^43
 ;;^UTILITY(U,$J,358.3,16630,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16630,1,3,0)
 ;;=3^625.6
 ;;^UTILITY(U,$J,358.3,16630,1,4,0)
 ;;=4^Fem Stress Incontinence
 ;;^UTILITY(U,$J,358.3,16630,2)
 ;;=^114717
 ;;^UTILITY(U,$J,358.3,16631,0)
 ;;=V53.99^^108^1046^46
 ;;^UTILITY(U,$J,358.3,16631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16631,1,3,0)
 ;;=3^V53.99
 ;;^UTILITY(U,$J,358.3,16631,1,4,0)
 ;;=4^Fit/Adjust Device NEC
 ;;^UTILITY(U,$J,358.3,16631,2)
 ;;=^329974
 ;;^UTILITY(U,$J,358.3,16632,0)
 ;;=611.71^^108^1046^57
 ;;^UTILITY(U,$J,358.3,16632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16632,1,3,0)
 ;;=3^611.71
 ;;^UTILITY(U,$J,358.3,16632,1,4,0)
 ;;=4^Mastodynia
 ;;^UTILITY(U,$J,358.3,16632,2)
 ;;=^74467
 ;;^UTILITY(U,$J,358.3,16633,0)
 ;;=622.7^^108^1046^60
 ;;^UTILITY(U,$J,358.3,16633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16633,1,3,0)
 ;;=3^622.7
 ;;^UTILITY(U,$J,358.3,16633,1,4,0)
 ;;=4^Mucous Polyp of Cervix
 ;;^UTILITY(U,$J,358.3,16633,2)
 ;;=^79612
 ;;^UTILITY(U,$J,358.3,16634,0)
 ;;=795.02^^108^1046^65
 ;;^UTILITY(U,$J,358.3,16634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16634,1,3,0)
 ;;=3^795.02
 ;;^UTILITY(U,$J,358.3,16634,1,4,0)
 ;;=4^Pap Smear (ASC-H)
 ;;^UTILITY(U,$J,358.3,16634,2)
 ;;=^331973
 ;;^UTILITY(U,$J,358.3,16635,0)
 ;;=795.01^^108^1046^66
 ;;^UTILITY(U,$J,358.3,16635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16635,1,3,0)
 ;;=3^795.01
 ;;^UTILITY(U,$J,358.3,16635,1,4,0)
 ;;=4^Pap Smear (ASC-US)
 ;;^UTILITY(U,$J,358.3,16635,2)
 ;;=^331972
 ;;^UTILITY(U,$J,358.3,16636,0)
 ;;=795.04^^108^1046^67
 ;;^UTILITY(U,$J,358.3,16636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16636,1,3,0)
 ;;=3^795.04
 ;;^UTILITY(U,$J,358.3,16636,1,4,0)
 ;;=4^Pap Smear Cervix w/ HGSIL
 ;;^UTILITY(U,$J,358.3,16636,2)
 ;;=^331572
 ;;^UTILITY(U,$J,358.3,16637,0)
 ;;=795.03^^108^1046^68
 ;;^UTILITY(U,$J,358.3,16637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16637,1,3,0)
 ;;=3^795.03
 ;;^UTILITY(U,$J,358.3,16637,1,4,0)
 ;;=4^Pap Smear Cervix w/ LGSIL
 ;;^UTILITY(U,$J,358.3,16637,2)
 ;;=^331571
 ;;^UTILITY(U,$J,358.3,16638,0)
 ;;=256.4^^108^1046^73
 ;;^UTILITY(U,$J,358.3,16638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16638,1,3,0)
 ;;=3^256.4
 ;;^UTILITY(U,$J,358.3,16638,1,4,0)
 ;;=4^Polycystic Ovaries
 ;;^UTILITY(U,$J,358.3,16638,2)
 ;;=^96086
 ;;^UTILITY(U,$J,358.3,16639,0)
 ;;=627.0^^108^1046^78
 ;;^UTILITY(U,$J,358.3,16639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16639,1,3,0)
 ;;=3^627.0
